Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).
2016 ◽
Vol 34
(15_suppl)
◽
pp. 500-500
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 585-585
◽
2020 ◽
Keyword(s):
2022 ◽
Keyword(s):